Towards a Chlamydia trachomatis vaccine: How close are we?

Future Microbiology

Volumn 5, Issue 12, 2010, Pages 1833-1856

  Cochrane, Melanie ^a   Armitage, Charles W ^a   Omeara, Connor P ^a   Beagley, Kenneth W ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Adjuvant; Antigen; Chlamydia; Vaccine

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL ANTIGEN; BACTERIAL VACCINE; CHOLERA TOXIN; EPITOPE OF CMU POLYMORPHIC MEMBRANE PROTEIN F; GAMMA INTERFERON; GENOMIC DNA; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 70; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INDOLEAMINE 2,3 DIOXYGENASE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 1BETA CONVERTING ENZYME; MAJOR OUTER MEMBRANE PROTEIN; OUTER MEMBRANE PROTEIN; OUTER SURFACE PROTEIN A; RECOMBINANT CHLAMYDIAL PROTEASE LIKE ACTIVITY FACTOR; RECOMBINANT LIPIDATED BORRELIA BURGDORFERI OUTER-SURFACE PROTEIN A; RECOMBINANT RIBONUCLEOSIDE REDUCTASE SMALL CHAIN PROTEIN; T LYMPHOCYTE ANTIGEN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTIBIOTIC THERAPY; ANTIBODY RESPONSE; CHLAMYDIA; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; COMPUTER MODEL; DISEASE DURATION; DNA FRAGMENTATION; DRUG DELIVERY SYSTEM; ECTOPIC PREGNANCY; EPIDIDYMITIS; EPITHELIUM CELL; FIBROBLAST; GENE IDENTIFICATION; GUINEA PIG; HELPER CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNITY; IMMUNOPATHOGENESIS; INFERTILITY; INFLAMMATORY DISEASE; MACROPHAGE; MALE INFERTILITY; MONOCYTE; MOUSE; NONHUMAN; ORCHITIS; OUTCOME ASSESSMENT; PELVIC INFLAMMATORY DISEASE; PHARYNGITIS; PRIMATE; PRIORITY JOURNAL; PROCTITIS; PROSTATITIS; PROTEIN EXPRESSION; PROTEOMICS; RADIOIMMUNOPRECIPITATION; REVIEW; SALPINGITIS; SEVERE COMBINED IMMUNODEFICIENCY; SEXUALLY TRANSMITTED DISEASE; TWO DIMENSIONAL ELECTROPHORESIS; URETHRITIS; UROGENITAL TRACT INFECTION; VACCINE PRODUCTION; WESTERN BLOTTING;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL VACCINES; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNIZATION;

BACTERIA (MICROORGANISMS); CHLAMYDIA; CHLAMYDIA TRACHOMATIS;

EID: 78650503276     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.10.148     Document Type: Review

References (187)

1. WHO: Global prevalence and incidence of selected curable sexually transmitted infections: overview and estimates. WHO, Geneva, Switzerland (2001).
2. Westrom L: Chlamydia and its effect on reproduction. J. Br. Fer. Soc. 1(1), 23-30 (1996).
3. US Department of Health and Human Services, Centres for disease control and prevention (CDC): Sexually Transmitted Disease Surveillance 2008. Atlanta, GA, USA (2008)
4. Peipert J: Clinical practice. Genital chlamydial infections. N. Engl. J. Med. 349(25), 2424-2430 (2003).
5. Dodd R: Quantifying the STD-HIV connection. AIDS Anal. Afr. 4(5), 16 (1994).
6. Dieterle S, Rummel C, Bader L, Petersen H, Fenner T: Presence of the major outer-membrane protein of Chlamydia trachomatis in patients with chronic salpingitis and salpingitis isthmica nodosa with tubal occlusion. Fertil. Steril. 70(4), 774-776 (1998).
7. Cunningham K, Beagley K: Male genital tract chlamydial infection: Implications for pathology and infertility. Biol. Reprod. 79(2), 180-189 (2008).
8. Gallegos-Avila G, Alvarez-Cuevas S, Niderhauser-Garcia A, Ancer-Rodriguez J, Jaramillo-Rangel G, Ortega-Martinez M: Phagocytosis of spermatozoa and leucocytes by epithelial cells of the genital tract in infertile men infected with chlamydia trachomatis and mycoplasmas. Histopathology 55(2), 232-234 (2009).
9. Jungwirth A, Straberger A, Esterbauer B, Fink K, Schmeller N: Acrosome reaction in chlamydia-positive and negative patients. Andrologia 35(5), 314-316 (2003).
10. Gallegos G, Ramos B, Santiso R, Goyanes V, Gosalvez J, Fernandez Jl: Sperm DNA fragmentation in infertile men with genitourinary infection by Chlamydia trachomatis and Mycoplasma. Fertil. Steril. 90(2), 328-334 (2008).
11. Beagley K, Huston W, Hansbro P, Timms P: Chlamydial infection of immune cells: Altered function and implications for disease. Crit. Rev. Immunol. 29(4), 275-305 (2009).
12. Tipples G, Mcclarty G: The obligate intracellular bacterium Chlamydia trachomatis is auxotrophic for three of the four ribonucleoside triphosphates. Mol. Microbiol. 8(6), 1105-1114 (1993).
13. Pirbhai M, Dong F, Zhong Y, Pan K, Zhong G: The secreted protease factor CPAF is responsible for degrading pro-apoptotic BH3-only proteins in Chlamydia trachomatis-infected cells. J. Biol. Chem. 281(42), 31495-31501 (2006).
14. Hybiske K, Stephens R: Mechanisms of Chlamydia trachomatis entry into nonphagocytic cells. Infect. Immun. 75(8), 3925-3934 (2007).
15. Peterson E, Cheng X, Motin V, De La Maza L: Effect of immunoglobulin G isotype on the infectivity of Chlamydia trachomatis in a mouse model of intravaginal infection. Infect. Immun. 65(7), 2693-2699 (1997).
16. Hackstadt T, Fischer E, Scidmore M, Rockey D, Heinzen R: Origins and functions of the chlamydial inclusion. Trends Microbiol. 5(7), 288-293 (1997).
17. Hogbom M, Stenmark P, Voevodskaya N, Mcclarty G, Graslund A, Nordlund P: The radical site in chlamydial ribonucleotide reductase defines a new R2 subclass. Science 305(5681), 245-248 (2004).
18. Zhong Y, Weininger M, Pirbhai M, Dong F, Zhong G: Inhibition of staurosporine-induced activation of the proapoptotic multidomain BCL-2 proteins bax and bak by three invasive chlamydial species. J. Infect. 53(6), 408-414 (2006).
19. Bohme L, Albrecht M, Riede O, Rudel T: Chlamydia trachomatis-infected host cells resist dsRNA-induced apoptosis. Cell. Microbiol. 6, 6 (2010).
20. Fan T, Lu H, Hu H et al.: Inhibition of apoptosis in chlamydia-infected cells: blockade of mitochondrial cytochrome c release and caspase activation. J. Exp. Med. 187(4), 487-496 (1998).
21. Zhong G, Liu L, Fan T, Fan P, Ji H: Degradation of transcription factor rfx5 during the inhibition of both constitutive and interferon g-inducible major histocompatibility complex class I expression in chlamydia-infected cells. J. Exp. Med. 191(9), 1525-1534 (2000).
22. Zhong G, Fan T, Liu L: Chlamydia inhibits interferon g-inducible major histocompatibility complex class II expression by degradation of upstream stimulatory factor 1. J. Exp. Med. 189(12), 1931-1938 (1999).
23. Jendro M, Fingerle F, Deutsch T et al.: Chlamydia trachomatis-infected macrophages induce apoptosis of activated T cells by secretion of tumor necrosis factor-a in vitro. Med. Microbiol. Immunol. 193(1), 45-52 (2004).
24. Ingalls R, Rice P, Qureshi N, Takayama K, Lin J, Golenbock D: The inflammatory cytokine response to Chlamydia trachomatis infection is endotoxin mediated. Infect. Immun. 63(8), 3125-3130 (1995).
25. Skilton R, Cutcliffen L, Barlow D et al.: Penicillin induced persistence in Chlamydia trachomatis: high quality time lapse video analysis of the developmental cycle. PLoS One 4(11), E7723 (2009).
26. Beatty W, Belanger T, Desai A, Morrison R, Byrne G: Tryptophan depletion as a mechanism of g-interferon-mediated chlamydial persistence. Infect. Immun. 62(9), 3705-3711 (1994). (Pubitemid 24264310)
27. Wyrick P: Chlamydia trachomatis persistence in vitro: an overview. J. Infect. Dis. 201(Suppl. 2), S88-S95 (2010).
28. Pospischil A, Borel N, Chowdhury E, Guscetti F: Aberrant chlamydial developmental forms in the gastrointestinal tract of pigs spontaneously and experimentally infected with Chlamydia suis. Vet. Microbiol. 135(1-2), 147-156 (2009).
29. Dean D, Suchland R, Stamm W: Evidence for long term cervical persistence of Chlamydia trachomatis by OMP1 genotyping. J. Infect. Dis. 182(3), 909-916 (2000).
30. Carey A, Cunningham K, Hafner L, Timms P, Beagley K: Intranasal immunization against genital tract chlamydia infections during chlamydial infection induces persistent infections in the upper reproductive tract. Australasian Society for Immunology, 39th Annual Scientific Meeting. Queensland, Australia, 6-10 December 2009 (Abstract 132).
31. Hybiske K, Stephens R: Mechanisms of host cell exit by the intracellular bacterium Chlamydia. Proc. Natl Acad. Sci. USA 104(27), 11430-11435 (2007).
32. Lyons J, Ito J, Morre S: Chlamydia trachomatis serovar E isolates from patients with different clinical manifestations have similar courses of infection in a murine model: host factors as major determinants of C. trachomatis mediated pathogenesis. J. Clin. Pathol. 57(6), 657-659 (2004).
33. Vanrompay D, Lyons J, Morre S: Animal models for the study of Chlamydia trachomatis infections in the female genital infection. Drugs Today (Barc.) 42 Suppl. A, 55-63 (2006).
34. Van Voorhis W, Barrett L, Sweeney Y, Kuo C, Patton D: Repeated Chlamydia trachomatis infection of Macaca nemestrina fallopian tubes produces a TH1-like cytokine response associated with fibrosis and scarring. Infect. Immun. 65(6), 2175-2182 (1997).
35. Rank R, Bowlin A, Reed R, Darville T: Characterization of chlamydial genital infection resulting from sexual transmission from male to female guinea pigs and determination of infectious dose. Infect. Immun. 71(11), 6148-6154 (2003).
36. Read T, Brunham R, Shen C et al.: Genome sequences of Chlamydia trachomatis mopn and Chlamydia pneumoniae AR39. Nucl. Acids Res. 28(6), 1397-1406 (2000).
37. Coers J, Starnbach M, Howard J: Modeling infectious disease in mice: co-adaptation and the role of host-specific IFNg responses. PLoS Pathog. 5(5), E1000333 (2009).
38. Brunham R, Rey-Ladino J: Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nat. Rev. Immunol. 5(2), 149-161 (2005).
39. Morrison R, Caldwell H: Immunity to murine chlamydial genital infection. Infect. Immun. 70(6), 2741-2751 (2002).
40. Roshick C, Wood H, Caldwell HD, McClarty G: Comparison of g-interferon-mediated antichlamydial defense mechanisms in human and mouse cells. Infect. Immun. 74(1), 225-238 (2006).
41. Nelson D, Virok D, Wood H et al.: Chlamydial IFN-g immune evasion is linked to host infection tropism. PNAS 102(30), 10658-10663 (2005).
42. Caldwell H, Wood H, Crane D et al.: Polymorphisms in Chlamydia trachomatis tryptophan synthase genes differentiate between genital and ocular isolates. J. Clin. Invest. 111(11), 1757-1769 (2003).
43. Ito J, Lyons J, Airo-Brown L: Variation in virulence among oculogenital serovars of Chlamydia trachomatis in experimental genital tract infection. Infect. Immun. 58(6), 2021-2023 (1990).
44. Shah A, Schripsema J, Imtiaz M et al.: Histopathologic changes related to fibrotic oviduct occlusion after genital tract infection of mice with Chlamydia muridarum. Sex. Transm. Dis. 32(1), 49-56 (2005).
45. Cotter T, Ramsey K, Miranpuri G, Poulsen C, Byrne G: Dissemination of Chlamydia trachomatis chronic genital tract infection in g interferon gene knockout mice. Infect. Immun. 65(6), 2145-2152 (1997).
46. Cotter T, Miranpuri G, Ramsey K, Poulsen C, Byrne G: Reactivation of chlamydial genital tract infection in mice. Infect. Immun. 65(6), 2067-2073 (1997).
47. Rank R, Ramsey K, Pack E, Williams D: Effect of g interferon on resolution of murine chlamydial genital infection. Infect. Immun. 60(10), 4427-4429 (1992).
48. Ramsey K, Sigar I, Schripsema J et al.: Strain and virulence diversity in the mouse pathogen Chlamydia muridarum. Infect. Immun. 77(8), 3284-3293 (2009).
49. Coers J, Bernstein-Hanley I, Grotsky D et al.: Chlamydia muridarum evades growth restriction by the IFN-g-inducible host resistance factor irgb10. J. Immunol. 180(9), 6237-6245 (2008).
50. Woolridge R, Grayston J, Perrin E, Yang C, Cheng K, Chang I: Natural history of trachoma in Taiwan school children. Am. J. Ophthalmol. 63(5 Suppl.), 1313-1320 (1967).
51. Stephens R: The cellular paradigm of chlamydial pathogenesis. Trends Microbiol. 11(1), 44-51 (2003).
52. Darville T, Hiltke T: Pathogenesis of genital tract disease due to Chlamydia trachomatis. J. Infect. Dis 201(Suppl. 2), S114-S125 (2010).
53. Hvid M, Baczynska A, Deleuran B et al.: Interleukin-1 is the initiator of fallopian tube destruction during Chlamydia trachomatis infection. Cell. Microbiol. 9(12), 2795-2803 (2007).
54. Lee H, Schripsema J, Sigar I, Murray C, Lacy S, Ramsey K: A link between neutrophils and chronic disease manifestations of Chlamydia muridarum urogenital infection of mice. FEMS Immunol. Med. Microbiol. 59(1), 108-116 (2010).
55. Bachmaier K, Penninger J: Chlamydia and antigenic mimicry. Curr. Top. Microbiol. Immunol. 296, 153-163 (2005).
56. Swanborg R, Boros D, Whittum-Hudson J, Hudson A: Molecular mimicry and horror autotoxicus: do chlamydial infections elicit autoimmunity? Expert Rev. Mol. Med. 8(29), 1-23 (2006).
57. Rank R, Sanders M, Patton D: Increased incidence of oviduct pathology in the guinea pig after repeat vaginal inoculation with the chlamydial agent of guinea pig inclusion conjunctivitis. Sex. Transm. Dis. 22(1), 48-54 (1995).
58. Peeling R, Kimani J, Plummer F et al.: Antibody to chlamydial hsp60 predicts an increased risk for chlamydial pelvic inflammatory disease. J. Infect. Dis 175(5), 1153-1158 (1997).
59. Ness R, Soper D, Richter H et al.: Chlamydia antibodies, chlamydia heat shock protein, and adverse sequelae after pelvic inflammatory disease: the PID evaluation and clinical health (PEACH) study. Sex. Transm. Dis. 35(2), 129-135 (2008).
60. Bai H, Cheng J, Gao X et al.: Il-17/TH17 promotes type 1 T cell immunity against pulmonary intracellular bacterial infection through modulating dendritic cell function. J. Immunol. 183(9), 5886-5895 (2009).
61. Happel K, Dubin P, Zheng M et al.: Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniae. J. Exp. Med. 202(6), 761-769 (2005).
62. Kohyama S, Ohno S, Isoda A et al.: IL-23 enhances host defense against vaccinia virus infection via a mechanism partly involving IL-17. J. Immunol. 179(6), 3917-3925 (2007).
63. Lim A, Allison C, Price P, Waterer G: Susceptibility to pulmonary disease due to Mycobacterium avium-intracellulare complex may reflect low IL-17 and high IL-10 responses rather than TH1 deficiency. Clin. Immunol. 137(2), 296-302 (2010).
64. Wozniak T, Saunders B, Ryan A, Britton W: Mycobacterium bovis BCG-specific TH17 cells confer partial protection against Mycobacterium tuberculosis infection in the absence of g interferon. Infect. Immun. 78(10), 4187-4194 (2010).
65. Langrish C, Chen Y, Blumenschein W et al.: IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201(2), 233-240 (2005).
66. Yen D, Cheung J, Scheerens H et al.: IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest. 116(5), 1310-1316 (2006).
67. Lubberts E, Koenders M, Oppers-Walgreen B et al.: Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum. 50(2), 650-659 (2004).
68. Kolls J, Kanaly S, Ramsay A: Interleukin-17: an emerging role in lung inflammation. Am. J. Respir. Cell. Mol. Biol. 28(1), 9-11 (2003).
69. Zhang X, Gao L, Lei L et al.: A MyD88- dependent early IL-17 production protects mice against airway infection with the obligate intracellular pathogen Chlamydia muridarum. J. Immunol. 183(2), 1291-1300 (2009).
70. Zhou X, Chen Q, Moore J, Kolls J, Halperin S, Wang J: Critical role of the interleukin-17/interleukin-17 receptor axis in regulating host susceptibility to respiratory infection with Chlamydia species. Infect. Immun. 77(11), 5059-5070 (2009).
71. Brunham R, Pourbohloul B, Mak S, White R, Rekart M: The unexpected impact of a Chlamydia trachomatis infection control program on susceptibility to reinfection. J. Infect. Dis 192(10), 1836-1844 (2005).
72. Brunham R, Rekart M: The arrested immunity hypothesis and the epidemiology of chlamydia control. Sex. Transm. Dis. 35(1), 53-54 (2008).
73. Su H, Morrison R, Messer R, Whitmire W, Hughes S, Caldwell H: The effect of doxycycline treatment on the development of protective immunity in a murine model of chlamydial genital infection. J. Infect. Dis 180(4), 1252-1258 (1999).
74. De La Maza M, De La Maza L: A new computer model for estimating the impact of vaccination protocols and its application to the study of Chlamydia trachomatis genital infections. Vaccine 13(1), 119-127 (1995).
75. Gray R, Beagley K, Timms P, Wilson D: Modeling the impact of potential vaccines on epidemics of sexually transmitted Chlamydia trachomatis infection. J. Infect. Dis 199(11), 1680-1688 (2009).
76. Wang J, Chen L, Chen F et al.: A chlamydial type III-secreted effector protein (tarp) is predominantly recognized by antibodies from humans infected with Chlamydia trachomatis and induces protective immunity against upper genital tract pathologies in mice. Vaccine 27(22), 2967-2980 (2009).
77. Ekong E, Okenu D, Mania-Pramanik J et al.: A Vibrio cholerae ghost-based subunit vaccine induces cross-protective chlamydial immunity that is enhanced by CTA2b, the nontoxic derivative of cholera toxin. FEMS Immunol. Med. Microbiol. 55(2), 280-291 (2009).
78. Li W, Guentzel M, Seshu J, Zhong G, Murthy A, Arulanandam B: Induction of cross-serovar protection against genital chlamydial infection by a targeted multisubunit vaccination approach. Clin. Vaccine Immunol. 14(12), 1537-1544 (2007).
79. Yule T, Tung K: Experimental autoimmune orchitis induced by testis and sperm antigen-specific T cell clones: an important pathogenic cytokine is tumor necrosis factor. Endocrinology 133(3), 1098-1107 (1993).
80. Beatty W, Byrne G, Morrison R: Morphologic and antigenic characterization of interferon g-mediated persistent Chlamydia trachomatis infection in vitro. Proc. Natl Acad. Sci. USA 90(9), 3998-4002 (1993).
81. Rodolakis A, Bernard F: Vaccination with temperature-sensitive mutant of Chlamydia psittaci against enzootic abortion of ewes. Vet. Rec. 114(8), 193-194 (1984).
82. Rodolakis A, Salinas J, Papp J: Recent advances on ovine chlamydial abortion. Vet. Res. 29(3-4), 275-288 (1998).
83. Chalmers W, Simpson J, Lee S, Baxendale W: Use of a live chlamydial vaccine to prevent ovine enzootic abortion. Vet. Rec. 141(3), 63-67 (1997).
84. Longbottom D, Livingstone M: Vaccination against chlamydial infections of man and animals. Vet. J. 171(2), 263-275 (2006).
85. Grayston J, Wang S, Yeh L, Kuo C: Importance of reinfection in the pathogenesis of trachoma. Rev. Infect. Dis. 7(6), 717-725 (1985).
86. Dhir S, Agarwal L, Gupta S, Detels R, Wang S, Grayston J: Trachoma vaccine trial in india: results of two-year follow-up. Indian J. Med. Res. 56(8), 1289-1294 (1968).
87. Dhir S, Agarwal L, Detels R, Wang S, Grayston J: Field trial of two bivalent trachoma vaccines in children of Punjab Indian villages. Am. J. Ophthalmol. 63(5 Suppl.), 1639-1644 (1967).
88. Grayston J, Wang S, Yang Y, Woolridge R: The effect of trachoma virus vaccine on the course of experimental trachoma infection in blind human volunteers. J. Exp. Med. 115(5), 1009-1022 (1962).
89. Benagiano M, Delios M, Amedei A et al.: Human 60-kda heat shock protein is a target autoantigen of T cells derived from atherosclerotic plaques. J. Immunol. 174(10), 6509-6517 (2005).
90. Olivares-Zavaleta N, Whitmire W, Gardner D, Caldwell H: Immunization with the attenuated plasmidless Chlamydia trachomatis L2(25667r) strain provides partial protection in a murine model of female genitourinary tract infection. Vaccine 28(6), 1454-1462 (2010).
91. Rockey D, Wang J, Lei L, Zhong G: Chlamydia vaccine candidates and tools for chlamydial antigen discovery. Expert Rev. Vaccines 8(10), 1365-1377 (2009).
92. Sanchez-Campillo M, Bini L, Comanducci M et al.: Identification of immunoreactive proteins of Chlamydia trachomatis by Western blot analysis of a two-dimensional electrophoresis map with patient sera. Electrophoresis 20(11), 2269-2279 (1999).
93. Shaw A, Vandahl B, Larsen M et al.: Characterization of a secreted chlamydia protease. Cell. Microbiol. 4(7), 411-424 (2002).
94. Wolf K, Fischer E, Mead D et al.: Chlamydia pneumoniae major outer membrane protein is a surface-exposed antigen that elicits antibodies primarily directed against conformation-dependent determinants. Infect. Immun. 69(5), 3082-3091 (2001).
95. Sharma J, Zhong Y, Dong F, Piper J, Wang G, Zhong G: Profiling of human antibody responses to Chlamydia trachomatis urogenital tract infection using microplates arrayed with 156 chlamydial fusion proteins. Infect. Immun. 74(3), 1490-1499 (2006).
96. Grotenbreg G, Roan N, Guillen E et al.: Discovery of CD8+ T cell epitopes in Chlamydia trachomatis infection through use of caged class I MHC tetramers. Proc. Natl Acad. Sci. USA 105(10), 3831-3836 (2008).
97. Starnbach M, Loomis W, Ovendale P et al.: An inclusion membrane protein from Chlamydia trachomatis enters the MHC class I pathway and stimulates a CD8+ T cell response. J. Immunol. 171(9), 4742-4749 (2003).
98. Karunakaran K, Rey-Ladino J, Stoynov N et al.: Immunoproteomic discovery of novel T cell antigens from the obligate intracellular pathogen chlamydia. J. Immunol. 180(4), 2459-2465 (2008).
99. Yu H, Jiang X, Shen C, Karunakaran K, Brunham R: Novel Chlamydia muridarum T cell antigens induce protective immunity against lung and genital tract infection in murine models. J. Immunol. 182(3), 1602-1608 (2009).
100. Yu H, Jiang X, Shen C et al.: Chlamydia muridarum T-cell antigens formulated with the adjuvant dda/tdb induce immunity against infection that correlates with a high frequency of g interferon (IFN-g)/tumor necrosis factor a and IFN-g/interleukin-17 double-positive CD4+ T cells. Infect. Immun. 78(5), 2272-2282 (2010).
101. Kinnunen A, Molander P, Morrison R et al.: Chlamydial heat shock protein 60-specific T cells in inflamed salpingeal tissue. Fertil. Steril. 77(1), 162-166 (2002).
102. McNeilly C, Beagley K, Moore R, Haring V, Timms P, Hafner L: Expression library immunization confers partial protection against Chlamydia muridarum genital infection. Vaccine 25(14), 2643-2655 (2007).
103. Rabasseda X, Morre S, Ouburg S: Bioinformatic approaches to the study of chlamydial diseases. Drugs Today (Barc.) 45(Suppl. B), 173-187 (2009).
104. Barker C, Beagley K, Hafner L, Timms P: In silico identification and in vivo analysis of a novel T-cell antigen from chlamydia, NrdB. Vaccine 26(10), 1285-1296 (2008).
105. Caldwell H, Kromhout J, Schachter J: Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis. Infect. Immun. 31(3), 1161-1176 (1981).
106. Ward ME: Chlamydial vaccines - future trends. J. Infect. 25(Suppl. 1), 11-26 (1992).
107. Brunham R, Peeling R: Chlamydia trachomatis antigens: role in immunity and pathogenesis. Infect. Agents Dis. 3(5), 218-233 (1994).
108. Bavoil P, Ohlin A, Schachter J: Role of disulfide bonding in outer membrane structure and permeability in Chlamydia trachomatis. Infect. Immun. 44(2), 479-485 (1984).
109. Wyllie S, Ashley R, Longbottom D, Herring A: The major outer membrane protein of Chlamydia psittaci functions as a porin-like ion channel. Infect. Immun. 66(11), 5202-5207 (1998).
110. Su H, Watkins N, Zhang Y, Caldwell H: Chlamydia trachomatis-host cell interactions: role of the chlamydial major outer membrane protein as an adhesin. Infect. Immun. 58(4), 1017-1025 (1990). (Pubitemid 20117034)
111. Hickey D, Aldwell F, Beagley K: Transcutaneous immunization with a novel lipid-based adjuvant protects against chlamydia genital and respiratory infections. Vaccine 27(44), 6217-6225 (2009).
112. Hafner L, Beagley K, Timms P: Chlamydia trachomatis infection: host immune responses and potential vaccines. Mucosal Immunol. 1(2), 116-130 (2008).
113. Cunningham K, Carey A, Lycke N, Timms P, Beagley K: CTA1-DD is an effective adjuvant for targeting anti-chlamydial immunity to the murine genital mucosa. J. Reprod. Immunol. 81(1), 34-38 (2009).
114. Coler R, Bhatia A, Maisonneuve J et al.: Identification and characterization of novel recombinant vaccine antigens for immunization against genital Chlamydia trachomatis. FEMS Immunol. Med. Microbiol. 55(2), 258-270 (2009).
115. Champion C, Kickhoefer V, Liu G et al.: A vault nanoparticle vaccine induces protective mucosal immunity. PLoS One 4(4), E5409 (2009).
116. Li W, Murthy A, Guentzel M et al.: Antigen-specific CD4+ T cells produce sufficient IFN-g to mediate robust protective immunity against genital Chlamydia muridarum infection. J. Immunol. 180(5), 3375-3382 (2008).
117. Pal S, Luke C, Barbour A, Peterson E, De La Maza L: Immunization with the Chlamydia trachomatis major outer membrane protein, using the outer surface protein a of Borrelia burgdorferi as an adjuvant, can induce protection against a chlamydial genital challenge. Vaccine 21(13-14), 1455-1465 (2003).
118. Skelding K, Hickey D, Horvat J et al.: Comparison of intranasal and transcutaneous immunization for induction of protective immunity against Chlamydia muridarum respiratory tract infection. Vaccine 24(3), 355-366 (2006).
119. Abdelrahman Y, Belland R: The chlamydial developmental cycle. FEMS Microbiol. Rev. 29(5), 949-959 (2005).
120. Hickey D, Aldwell F, Beagley K: Oral immunization with a novel lipid-based adjuvant protects against genital chlamydia infection. Vaccine 28(7), 1668-1672 (2010).
121. Wang S, Grayston J: Classification of trachoma virus strains by protection of mice from toxic death. J. Immunol. 90, 849-856 (1963).
122. Wang S, Kuo C, Barnes R, Stephens R, Grayston J: Immunotyping of Chlamydia trachomatis with monoclonal antibodies. J. Infect. Dis 152(4), 791-800 (1985).
123. Mossman D, Beagley K, Landay A et al.: Genotyping of urogenital Chlamydia trachomatis in regional New South Wales, Australia. Sex. Transm. Dis. 35(6), 614-616 (2008).
124. Pal S, Peterson E, De La Maza L: Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria. Infect. Immun. 73(12), 8153-8160 (2005).
125. Kari L, Whitmire W, Crane D et al.: Chlamydia trachomatis native major outer membrane protein induces partial protection in nonhuman primates: implication for a trachoma transmission-blocking vaccine. J. Immunol. 182(12), 8063-8070 (2009).
126. Sun G, Pal S, Weiland J, Peterson E, De La Maza L: Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein. Vaccine 27(36), 5020-5025 (2009).
127. Pal S, Bravo J, Peterson E, De La Maza L: Protection of wild-type and severe combined immunodeficiency mice against an intranasal challenge by passive immunization with monoclonal antibodies to the Chlamydia trachomatis mouse pneumonitis major outer membrane protein. Infect. Immun. 76(12), 5581-5587 (2008).
128. Pal S, Theodor I, Peterson E, De La Maza L: Monoclonal immunoglobulin a antibody to the major outer membrane protein of the Chlamydia trachomatis mouse pneumonitis biovar protects mice against a chlamydial genital challenge. Vaccine 15(5), 575-582 (1997).
129. Sharma J, Dong F, Pirbhai M, Zhong G: Inhibition of proteolytic activity of a chlamydial proteasome/protease-like activity factor by antibodies from humans infected with Chlamydia trachomatis. Infect. Immun. 73(7), 4414-4419 (2005).
130. Dong F, Zhong Y, Arulanandam B, Zhong G: Production of a proteolytically active protein, chlamydial protease/ proteasome-like activity factor, by five different chlamydia species. Infect. Immun. 73(3), 1868-1872 (2005).
131. Zhong G, Fan P, Ji H, Dong F, Huang Y: Identification of a chlamydial protease-like activity factor responsible for the degradation of host transcription factors. J. Exp. Med. 193(8), 935-942 (2001).
132. Dong F, Su H, Huang Y, Zhong Y, Zhong G: Cleavage of host keratin 8 by a chlamydia-secreted protease. Infect. Immun. 72(7), 3863-3868 (2004).
133. Savijoki K, Alvesalo J, Vuorela P, Leinonen M, Kalkkinen N: Proteomic analysis of Chlamydia pneumoniae-infected hl cells reveals extensive degradation of cytoskeletal proteins. FEMS Immunol. Med. Microbiol. 54(3), 375-384 (2008).
134. Sharma J, Bosnic A, Piper J, Zhong G: Human antibody responses to a chlamydia-secreted protease factor. Infect. Immun. 72(12), 7164-7171 (2004).
135. Chaganty B, Murthy A, Evani S et al.: Heat denatured enzymatically inactive recombinant chlamydial protease-like activity factor induces robust protective immunity against genital chlamydial challenge. Vaccine 28(11), 2323-2329 (2010).
136. Murthy A, Chambers J, Meier P, Zhong G, Arulanandam B: Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous g interferon production. Infect. Immun. 75(2), 666-676 (2007).
137. Cong Y, Jupelli M, Guentzel M, Zhong G, Murthy A, Arulanandam B: Intranasal immunization with chlamydial protease-like activity factor and CpG deoxynucleotides enhances protective immunity against genital Chlamydia muridarum infection. Vaccine 25(19), 3773-3780 (2007).
138. Murthy A, Cong Y, Murphey C et al.: Chlamydial protease-like activity factor induces protective immunity against genital chlamydial infection in transgenic mice that express the human HLA-DR4 allele. Infect. Immun. 74(12), 6722-6729 (2006).
139. Murthy A, Chaganty B, Li W et al.: A limited role for antibody in protective immunity induced by rCPAF and CpG vaccination against primary genital Chlamydia muridarum challenge. FEMS Immunol. Med. Microbiol. 55(2), 271-279 (2009).
140. Mestecky J, Raska M, Novak J, Alexander R, Moldoveanu Z: Antibody-mediated protection and the mucosal immune system of the genital tract: relevance to vaccine design. J. Reprod. Immunol. 85(1), 81-85 (2010).
141. Sedgmen B, Meeusen E, Lofthouse S: Alternative routes of mucosal immunization in large animals. Immunol. Cell. Biol. 82(1), 10-16 (2004).
142. Nasir A: Nanotechnology in vaccine development: a step forward. J. Invest. Dermatol. 129(5), 1055-1059 (2009).
143. Hickey D, Jones R, Bao S et al.: Intranasal immunization with C. muridarum major outer membrane protein (MOMP) and cholera toxin elicits local production of neutralising IgA in the prostate. Vaccine 22(31-32), 4306-4315 (2004).
144. Berry L, Hickey Dk, Skelding K et al.: Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection. Infect. Immun. 72(2), 1019-1028 (2004).
145. De Haan L, Hirst T: Cholera toxin: a paradigm for multi-functional engagement of cellular mechanisms (review). Mol. Membr. Biol. 21(2), 77-92 (2004).
146. Van Ginkel F, Jackson R, Yuki Y, McGhee J: Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J. Immunol. 165(9), 4778-4782 (2000).
147. Mutsch M, Zhou W, Rhodes P et al.: Use of the inactivated intranasal influenza vaccine and the risk of bells palsy in Switzerland. N. Engl. J. Med. 350(9), 896-903 (2004).
148. Agren L, Norin M, Lycke N, Lowenadler B: Hydrophobicity engineering of cholera toxin A1 subunit in the strong adjuvant fusion protein CTA1-DD. Protein Eng. 12(2), 173-178 (1999).
149. Guidry J, Cardenas L, Cheng E, Clements J: Role of receptor binding in toxicity, immunogenicity, and adjuvanticity of escherichia coli heat-labile enterotoxin. Infect. Immun. 65(12), 4943-4950 (1997).
150. Cheng C, Bettahi I, Cruz-Fisher M et al.: Induction of protective immunity by vaccination against Chlamydia trachomatis using the major outer membrane protein adjuvanted with CpG oligodeoxynucleotide coupled to the nontoxic B subunit of cholera toxin. Vaccine 15, 15 (2009).
151. Holmgren J, Harandi A, Czerkinsky C: Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Expert Rev. Vaccines 2(2), 205-217 (2003).
152. Sun J, Holmgren J, Czerkinsky C: Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc. Natl Acad. Sci. USA 91(23), 10795-10799 (1994).
153. Lycke N: ADP-ribosylating bacterial enzymes for the targeted control of mucosal tolerance and immunity. Ann. NY Acad. Sci. 1029, 193-208 (2004).
154. Agren L, Ekman L, Lowenadler B, Nedrud J, Lycke N: Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity. J. Immunol. 162(4), 2432-2440 (1999).
155. Lycke N: Targeted vaccine adjuvants based on modified cholera toxin. Curr. Mol. Med. 5(6), 591-597 (2005).
156. Sundling C, Schon K, Morner A et al.: CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization. J. Gen. Virol. 89(Pt 12), 2954-2964 (2008).
157. De Filette M, Ramne A, Birkett A et al.: The universal influenza vaccine m2e-hbc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. Vaccine 24(5), 544-551 (2006).
158. Akhiani A, Stensson A, Schon K, Lycke N: The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization. Scand. J. Immunol. 63(2), 97-105 (2006).
159. Andersen C, Dietrich J, Agger E, Lycke N, Lovgren K, Andersen P: The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis. Infect. Immun. 75(1), 408-416 (2007).
160. McNeal M, Basu M, Bean J et al.: Intrarectal immunization of mice with vp6 and either lt(r192g) or CTA1-DD as adjuvant protects against fecal rotavirus shedding after EDIM challenge. Vaccine 25(33), 6224-6231 (2007).
161. Eko F, Witte A, Huter V et al.: New strategies for combination vaccines based on the extended recombinant bacterial ghost system. Vaccine 17(13-14), 1643-1649 (1999).
162. Mahmood K, Bright R, Mytle N et al.: H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 26(42), 5393-5399 (2008).
163. Frech S, Dupont H, Bourgeois A et al.: Use of a patch containing heat-labile toxin from Escherichia coli against travellers diarrhoea: a Phase II, randomised, double-blind, placebo-controlled field trial. Lancet 371(9629), 2019-2025 (2008).
164. Combadiere B, Vogt A, Mahe B et al.: Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: a randomized Phase I trial. PLoS One 5(5), e10818 (2010).
165. Neutra M, Kozlowski P: Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 6(2), 148-158 (2006).
166. Frazer I: Measuring serum antibody to human papillomavirus following infection or vaccination. Gynecol. Oncol. 118(1 Suppl.), S8-S11 (2010).
167. Stanberry L, Spruance S, Cunningham A et al.: Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347(21), 1652-1661 (2002).
168. Olsson S, Kjaer S, Sigurdsson K et al.: Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum. Vaccin.
169. Carey A, Cunningham K, Hafner L, Timms P, Beagley K: Effects of inoculating dose on the kinetics of Chlamydia muridarum genital infection in female mice. Immunol. Cell. Biol. 87(4), 337-343 (2009).
170. Nagarajan U, Prantner D, Sikes J et al.: Type I interferon signaling exacerbates Chlamydia muridarum genital infection in a murine model. Infect. Immun. 76(10), 4642-4648 (2008).
171. Marks E, Verolin M, Stensson A, Lycke N: Differential CD28 and inducible costimulatory molecule signaling requirements for protective CD4+ T-cell-mediated immunity against genital tract chlamydia trachomatis infection. Infect. Immun. 75(9), 4638-4647 (2007).
172. Morrison S, Morrison R: A predominant role for antibody in acquired immunity to chlamydial genital tract reinfection. J. Immunol. 175(11), 7536-7542 (2005).
173. Chen L, Cheng W, Shivshankar P et al.: Distinct roles of CD28- and CD40L-mediated costimulation in the development of protective immunity and pathology during Chlamydia muridarum urogenital infection in mice. Infect. Immun. 77(7), 3080-3089 (2009).
174. Cheng W, Shivshankar P, Li Z, Chen L, Yeh I, Zhong G: Caspase-1 contributes to Chlamydia trachomatis-induced upper urogenital tract inflammatory pathologies without affecting the course of infection. Infect. Immun. 76(2), 515-522 (2008).
175. Prantner D, Darville T, Sikes J et al.: Critical role for interleukin-1b (IL-1b) during Chlamydia muridarum genital infection and bacterial replication-independent secretion of IL-1b in mouse macrophages. Infect. Immun. 77(12), 5334-5346 (2009).
176. Darville T, Oneill J, Andrews C, Nagarajan U, Stahl L, Ojcius D: Toll-like receptor-2, but not toll-like receptor-4, is essential for development of oviduct pathology in chlamydial genital tract infection. J. Immunol. 171(11), 6187-6197 (2003).
177. Den Hartog J, Lyons J, Ouburg S et al.: TLR4 in Chlamydia trachomatis infections: knockout mice, STD patients and women with tubal factor subfertility. Drugs Today (Barc.) 45(Suppl. B), 75-82 (2009).
178. Chen L, Lei L, Chang X et al.: Mice deficient in MyD88 develop a TH2-dominant response and severe pathology in the upper genital tract following Chlamydia muridarum infection. J. Immunol. 184(5), 2602-2610 (2010).
179. Morrison S, Morrison R: The protective effect of antibody in immunity to murine chlamydial genital tract reinfection is independent of immunoglobulin A. Infect. Immun. 73(9), 6183-6186 (2005).
180. Pal S, Sarcon A, De La Maza L: C3H male mice with severe combined immunodeficiency cannot clear a urethral infection with a human serovar of Chlamydia trachomatis. Infect. Immun. 77(12), 5602-5607 (2009).
181. Cunningham K, Carey A, Finnie J et al.: Poly-immunoglobulin receptor-mediated transport of IgA into the male genital tract is important for clearance of Chlamydia muridarum infection. Am J. Reprod. Immunol. 60(5), 405-414 (2008).
182. Oconnell C, Ingalls R, Andrews C Jr, Scurlock A, Darville T: Plasmid-deficient Chlamydia muridarum fail to induce immune pathology and protect against oviduct disease. J. Immunol. 179(6), 4027-4034 (2007).
183. Hansen J, Jensen K, Follmann F, Agger E, Theisen M, Andersen P: Liposome delivery of Chlamydia muridarum major outer membrane protein primes a TH1 response that protects against genital chlamydial infection in a mouse model. J. Infect. Dis 198(5), 758-767 (2008).
184. Olsen A, Theisen M, Christensen D, Follmann F, Andersen P: Protection against Chlamydia promoted by a subunit vaccine (CTH1) compared with a primary intranasal infection in a mouse genital challenge model. PLoS One 5(5), E10768 (2010).
185. Department of Health and Ageing: Number of notifications of chlamydial infection, Australia, in the period of 1991 to 2009 and year-to-date notifications for 2010 (2010) www9.health.gov.au/cda/Source/Rpt-3.cfm
186. Bioinformatics Center: ProPred: MHC class II binding peptide prediction server www.imtech.res.in/raghava/propred
187. SYFPEITHI: A database of MHC ligands and peptide motifs. Version 1.0 (2009) www.syfpeithi.de